What to Do When Acute Gout Flare Treatment Fails in Patients on Strong P-glycoprotein and/or CYP3A4 Inhibitors
Clinical Scenario
This protocol applies to patients with gout who are concurrently receiving strong P-glycoprotein and/or CYP3A4 inhibitors — including cyclosporin, clarithromycin, ketoconazole, and verapamil. This drug-interaction setting imposes critical prescribing constraints: co-prescription of colchicine with these agents must be avoided, as concurrent use significantly increases colchicine plasma concentrations and the risk of serious adverse effects.
Previous Treatment Step & Escalation Trigger
Initial acute flare management in this population used non-colchicine options — NSAIDs (such as naproxen or indomethacin), oral corticosteroids, or articular aspiration with corticosteroid injection. When that step did not achieve full resolution of joint pain and inflammation, the structured next-step protocol described here applies.
Next-Step Approach (partial overview)
The next step centres on urate-lowering therapy initiated cautiously with gradual upward titration, an NSAID-based flare prophylaxis strategy — colchicine remains contraindicated in this population — and specific lifestyle modifications; the complete titration schedule, targets, and monitoring guidance are in the full protocol.
Treatment Targets
- Serum uric acid <6 mg/dL (360 mmol/L), maintained lifelong
- Serum uric acid <5 mg/dL (300 mmol/L) for patients with severe gout, until total crystal dissolution
References
DOI: 10.1136/annrheumdis-2016-209707
- Colchicine should not be given to patients receiving strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin or clarithromycin.
- Co-prescription of colchicine with strong P-glycoprotein and/or CYP3A4 inhibitors should be avoided.
- A pharmacokinetic study showed that strong P-glycoprotein and/or CYP3A4 inhibitors such as cyclosporin, clarithromycin, verapamil and ketoconazole when prescribed with colchicine increased colchicine plasma concentration, thereby exposing patients to risk of serious side effects.
- In patients with normal kidney function, allopurinol is recommended for first-line ULT, starting at a low dose (100 mg/day) and increasing by 100 mg increments every 2-4 weeks if required, to reach the uricaemia target.
- If colchicine is not tolerated or is contraindicated, prophylaxis with NSAIDs at low dosage, if not contraindicated, should be considered.
- Every person with gout should receive advice regarding lifestyle: weight loss if appropriate and avoidance of alcohol (especially beer and spirits) and sugar-sweetened drinks, heavy meals and excessive intake of meat and seafood.
- Low-fat dairy products should be encouraged.
- Regular exercise should be advised.
View source ↗